{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T12:39:30Z","timestamp":1794746370666,"version":"4.9.1"},"reference-count":168,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,29]],"date-time":"2023-12-29T00:00:00Z","timestamp":1703808000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005371","name":"Hubei Polytechnic University","doi-asserted-by":"publisher","award":["22xjz16R"],"award-info":[{"award-number":["22xjz16R"]}],"id":[{"id":"10.13039\/501100005371","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","award":["2022BCE045"],"award-info":[{"award-number":["2022BCE045"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.biopha.2023.116113","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T19:54:32Z","timestamp":1704398072000},"page":"116113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment"],"prefix":"10.1016","volume":"171","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9620-0925","authenticated-orcid":false,"given":"Changhong","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinshu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmei","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Mei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7942","key":"10.1016\/j.biopha.2023.116113_bib1","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41586-022-05551-x","article-title":"BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network","volume":"613","author":"Sun","year":"2023","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22010351","article-title":"Molecular mechanisms of treatment resistance in glioblastoma","volume":"22","author":"Ou","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202000054","article-title":"Lipid-based nanocarriers for the treatment of glioblastoma","volume":"1","author":"Iturrioz-Rodr\u00edguez","year":"2021","journal-title":"Adv. Nanobiomed. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/nnm.12.185","article-title":"Nanoparticles for imaging and treating brain cancer","volume":"8","author":"Meyers","year":"2013","journal-title":"Nanomedine"},{"key":"10.1016\/j.biopha.2023.116113_bib5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2016.05.044","article-title":"Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases","volume":"235","author":"Saraiva","year":"2016","journal-title":"J. Control Release"},{"issue":"24","key":"10.1016\/j.biopha.2023.116113_bib6","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.2174\/1381612828666220608093639","article-title":"The therapeutic benefits of intravenously administrated nanoparticles in stroke and age-related neurodegenerative diseases","volume":"28","author":"Farhoudi","year":"2022","journal-title":"Curr. Pharm. Des."},{"issue":"31","key":"10.1016\/j.biopha.2023.116113_bib7","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.2174\/0929867325666180514113136","article-title":"Recent advances on glioblastoma multiforme and nano-drug carriers: a review","volume":"26","author":"Liao","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib8","doi-asserted-by":"crossref","DOI":"10.1208\/s12249-023-02555-2","article-title":"Lipid-based nanocarriers in the treatment of glioblastoma multiforme (GBM): challenges and opportunities","volume":"24","author":"Gupta","year":"2023","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib9","doi-asserted-by":"crossref","DOI":"10.1007\/s00005-021-00609-6","article-title":"Recent advances in the use of lipid-based nanoparticles against glioblastoma multiforme","volume":"69","author":"Ortega-Berlanga","year":"2021","journal-title":"Arch. Immunol. Ther. Exp. (Warsz.)"},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib10","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"issue":"5","key":"10.1016\/j.biopha.2023.116113_bib11","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1021\/acsnano.2c02347","article-title":"Surface modification of lipid-based nanoparticles","volume":"16","author":"Xu","year":"2022","journal-title":"ACS Nano"},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1021\/acsmaterialsau.3c00032","article-title":"Lipid-based nanoparticles for drug\/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development","volume":"3","author":"Mehta","year":"2023","journal-title":"ACS Mater. Au"},{"key":"10.1016\/j.biopha.2023.116113_bib13","article-title":"Physiological barriers and strategies of lipid\u2010based nanoparticles for nucleic acid drug delivery","author":"Hu","year":"2023","journal-title":"Adv. Mater."},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib14","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1021\/ar300048p","article-title":"Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges","volume":"45","author":"Gomes-da-Silva","year":"2012","journal-title":"Acc. Chem. Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202100109","article-title":"Lipid nanoparticles for drug delivery","volume":"2","author":"Xu","year":"2021","journal-title":"Adv. NanoBiomed. Res."},{"key":"10.1016\/j.biopha.2023.116113_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114861","article-title":"Lipid nanoparticle-mediated drug delivery to the brain","volume":"197","author":"Khare","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2023.116113_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2019.11.009","article-title":"The blood-brain barrier: physiology and strategies for drug delivery","volume":"165\u2013166","author":"Pandit","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7501","key":"10.1016\/j.biopha.2023.116113_bib18","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nature13324","article-title":"Mfsd2a is critical for the formation and function of the blood-brain barrier","volume":"509","author":"Ben-Zvi","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.116113_bib19","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3762\/bjnano.11.72","article-title":"Key for crossing the BBB with nanoparticles: the rational design","volume":"11","author":"Lombardo","year":"2020","journal-title":"Beilstein J. Nanotechnol."},{"key":"10.1016\/j.biopha.2023.116113_bib20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.addr.2018.10.011","article-title":"Neurotheranostics as personalized medicines","volume":"148","author":"Kevadiya","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.2217\/fon.11.58","article-title":"When tumor cells make blood vessels: implications for glioblastoma therapy","volume":"7","author":"Kofman","year":"2011","journal-title":"Future Oncol."},{"key":"10.1016\/j.biopha.2023.116113_bib22","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jconrel.2018.05.008","article-title":"Drug delivery challenges and future of chemotherapeutic nanomedicine for glioblastoma treatment","volume":"281","author":"Ganipineni","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2023.116113_bib23","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2022.03.019","article-title":"Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers","volume":"345","author":"Farshbaf","year":"2022","journal-title":"J. Control Release"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib24","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.apsb.2018.01.004","article-title":"Liposomes and lipid disks traverse the BBB and BBTB as intact forms as revealed by two-step F\u00f6rster resonance energy transfer imaging","volume":"8","author":"Dai","year":"2018","journal-title":"Acta Pharm. Sin. B"},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib25","doi-asserted-by":"crossref","first-page":"7047","DOI":"10.3390\/ijms24087047","article-title":"Glioblastoma microenvironment and invasiveness: new insights and therapeutic targets","volume":"24","author":"Erices","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib26","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s004010100448","article-title":"Cytokine and cytokine receptor mRNA expression in human glioblastomas: evidence of Th1, Th2 and Th3 cytokine dysregulation","volume":"103","author":"Hao","year":"2002","journal-title":"Acta Neuropathol."},{"issue":"7621","key":"10.1016\/j.biopha.2023.116113_bib27","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature19364","article-title":"Ionic immune suppression within the tumour microenvironment limits T cell effector function","volume":"537","author":"Eil","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.116113_bib28","doi-asserted-by":"crossref","first-page":"vii9","DOI":"10.1093\/neuonc\/nov151","article-title":"Immunosuppressive mechanisms in glioblastoma","volume":"17","author":"Nduom","year":"2015","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib29","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib30","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s12032-019-1329-2","article-title":"The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications","volume":"37","author":"Tamura","year":"2019","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2023.116113_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.semcancer.2020.12.003","article-title":"Glioblastoma-initiating cell heterogeneity generated by the cell-of-origin, genetic\/epigenetic mutation and microenvironment","volume":"82","author":"Kondo","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib32","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1172\/JCI89587","article-title":"Overcoming therapeutic resistance in glioblastoma: the way forward","volume":"127","author":"Osuka","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6190","key":"10.1016\/j.biopha.2023.116113_bib33","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib34","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.gendis.2015.02.001","article-title":"Glioblastoma stem cells (GSCs) epigenetic plasticity and interconversion between differentiated non-GSCs and GSCs","volume":"2","author":"Safa","year":"2015","journal-title":"Genes Dis."},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib35","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.7150\/thno.38147","article-title":"Nanocarrier-based drug combination therapy for glioblastoma","volume":"10","author":"Zhao","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2023.116113_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2021.10.001","article-title":"Cancer cell heterogeneity and plasticity: from molecular understanding to therapeutic targeting","volume":"82","author":"Tang","year":"2022","journal-title":"Semin. Cancer Biol."},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib37","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3390\/pharmaceutics13081183","article-title":"Solid lipid nanoparticles (SLNs): an advanced drug delivery system targeting brain through BBB","volume":"13","author":"Satapathy","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib38","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ejpb.2014.05.004","article-title":"Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art","volume":"87","author":"Gastaldi","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib39","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1021\/acs.molpharmaceut.5b00081","article-title":"Cysteine-functionalized nanostructured lipid carriers for oral delivery of docetaxel: a permeability and pharmacokinetic study","volume":"12","author":"Fang","year":"2015","journal-title":"Mol. Pharm."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib40","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acs.bioconjchem.6b00705","article-title":"Apo E-functionalization of solid lipid nanoparticles enhances brain drug delivery: uptake mechanism and transport pathways","volume":"28","author":"Neves","year":"2017","journal-title":"Bioconj. Chem."},{"key":"10.1016\/j.biopha.2023.116113_bib41","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.jconrel.2022.03.047","article-title":"All-stage targeted therapy for glioblastoma based on lipid membrane coated cabazitaxel nanocrystals","volume":"345","author":"Wu","year":"2022","journal-title":"J. Control Release"},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib42","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1006\/bbrc.2002.6495","article-title":"Synergistic effect of cold mannitol and Na(+)\/Ca(2+) exchange blocker on blood-brain barrier opening","volume":"291","author":"Ikeda","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cnur.2017.01.002","article-title":"The use of mannitol and hypertonic saline therapies in patients with elevated intracranial pressure: a review of the evidence","volume":"52","author":"Witherspoon","year":"2017","journal-title":"Nurs. Clin. N. Am."},{"issue":"11","key":"10.1016\/j.biopha.2023.116113_bib44","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/pharmaceutics14112529","article-title":"Label-free assessment of mannitol accumulation following osmotic blood-brain barrier opening using chemical exchange saturation transfer magnetic resonance imaging","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib45","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.3390\/pharmaceutics13071084","article-title":"Focused ultrasound combined with microbubbles in central nervous system applications","volume":"13","author":"Chen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2023.116113_bib46","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2022.05.042","article-title":"Focused ultrasound\/microbubbles-assisted BBB opening enhances LNP-mediated mRNA delivery to brain","volume":"348","author":"Ogawa","year":"2022","journal-title":"J. Control Release"},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib47","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1088\/0031-9155\/60\/6\/2511","article-title":"Enhancement in blood-tumor barrier permeability and delivery of liposomal doxorubicin using focused ultrasound and microbubbles: evaluation during tumor progression in a rat glioma model","volume":"60","author":"Aryal","year":"2015","journal-title":"Phys. Med. Biol."},{"issue":"46","key":"10.1016\/j.biopha.2023.116113_bib48","doi-asserted-by":"crossref","DOI":"10.1002\/adma.201801362","article-title":"Overcoming the blood-brain barrier: the role of nanomaterials in treating neurological diseases","volume":"30","author":"Furtado","year":"2018","journal-title":"Adv. Mater."},{"key":"10.1016\/j.biopha.2023.116113_bib49","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/j.jconrel.2020.11.021","article-title":"Neurodegenerative diseases and effective drug delivery: a review of challenges and novel therapeutics","volume":"330","author":"Akhtar","year":"2021","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2023.116113_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib51","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: a current overview of in vivo studies","volume":"11","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2023.116113_bib52","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.2147\/IJN.S305851","article-title":"Improving drug delivery for alzheimer's disease through nose-to-brain delivery using nanoemulsions, nanostructured lipid carriers (NLC) and in situ hydrogels","volume":"16","author":"Cunha","year":"2021","journal-title":"Int. J. Nanomed."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib53","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40005-022-00589-5","article-title":"Drug delivery to the brain via the nasal route of administration: exploration of key targets and major consideration factors","volume":"53","author":"Jeong","year":"2023","journal-title":"J. Pharm. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib54","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.drudis.2019.10.005","article-title":"Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook","volume":"25","author":"Sabir","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib55","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s13346-022-01220-8","article-title":"Targeted nano-delivery of chemotherapy via intranasal route suppresses in vivo glioblastoma growth and prolongs survival in the intracranial mouse model","volume":"13","author":"Sandbhor","year":"2023","journal-title":"Drug Deliv. Transl. Res"},{"key":"10.1016\/j.biopha.2023.116113_bib56","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.06.053","article-title":"Quantitative analysis of drug delivery to the brain via nasal route","volume":"189","author":"Kozlovskaya","year":"2014","journal-title":"J. Control Release"},{"issue":"24","key":"10.1016\/j.biopha.2023.116113_bib57","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1021\/acschemneuro.1c00540","article-title":"Engineered solid lipid nanoparticles and nanostructured lipid carriers as new generations of blood\u2013brain barrier transmitters","volume":"12","author":"Amiri","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2023.116113_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114485","article-title":"Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: crossing or circumventing the blood\u2013brain barrier (BBB) to manage neurological disorders","volume":"189","author":"Correia","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2023.116113_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.118278","article-title":"Efficiency of lipid-based nano drug delivery systems in crossing the blood\u2013brain barrier: a review","volume":"346","author":"Khaledian","year":"2022","journal-title":"J. Mol. Liq."},{"issue":"9","key":"10.1016\/j.biopha.2023.116113_bib60","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s11095-021-03098-6","article-title":"Interactions of lipids, lipoproteins, and apolipoproteins with the blood-brain barrier","volume":"38","author":"Rhea","year":"2021","journal-title":"Pharm. Res"},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib61","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1177\/1087057113497981","article-title":"Significance of lipid composition in a blood-brain barrier\u2013mimetic PAMPA assay","volume":"19","author":"Campbell","year":"2014","journal-title":"SLAS Discov."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib62","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.3109\/10717544.2014.943337","article-title":"Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain","volume":"23","author":"Salunkhe","year":"2014","journal-title":"Drug Deliv."},{"issue":"40","key":"10.1016\/j.biopha.2023.116113_bib63","doi-asserted-by":"crossref","first-page":"15434","DOI":"10.1039\/C7NR05216B","article-title":"Enhanced blood brain barrier permeability and glioblastoma cell targeting via thermoresponsive lipid nanoparticles","volume":"9","author":"Rehman","year":"2017","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2023.116113_bib64","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ejpb.2018.10.017","article-title":"Solid lipid nanoparticles and nanostructured lipid carriers: a review emphasizing on particle structure and drug release","volume":"133","author":"Gordillo-Galeano","year":"2018","journal-title":"Eur. J. Pharma. Biopharma."},{"key":"10.1016\/j.biopha.2023.116113_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2020.113734","article-title":"Impact of liquid lipid on development and stability of trimyristin nanostructured lipid carriers for oral delivery of resveratrol","volume":"316","author":"Houacine","year":"2020","journal-title":"J. Mol. Liq."},{"issue":"1-2","key":"10.1016\/j.biopha.2023.116113_bib66","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2010.05.005","article-title":"Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability","volume":"394","author":"Zhuang","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2023.116113_bib67","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2020.111774","article-title":"Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB\/BBTB models","volume":"121","author":"Zwain","year":"2021","journal-title":"Mater. Sci. Engin: C"},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib68","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/17425247.2021.1902984","article-title":"Exploring the transformability of polymer-lipid hybrid nanoparticles and nanomaterial-biology interplay to facilitate tumor penetration, cellular uptake and intracellular targeting of anticancer drugs","volume":"18","author":"Amini","year":"2021","journal-title":"Expert Opin. Drug Deliv."},{"issue":"11","key":"10.1016\/j.biopha.2023.116113_bib69","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s11095-021-03122-9","article-title":"Optimizing the design of blood\u2013brain barrier-penetrating polymer-lipid-hybrid nanoparticles for delivering anticancer drugs to glioblastoma","volume":"38","author":"Ahmed","year":"2021","journal-title":"Pharm. Res."},{"key":"10.1016\/j.biopha.2023.116113_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioadv.2023.213660","article-title":"Overcoming biological barriers BBB\/BBTB by designing PUFA functionalised lipid-based nanocarriers for glioblastoma targeted therapy","volume":"155","author":"Zwain","year":"2023","journal-title":"Biomater. Adv."},{"key":"10.1016\/j.biopha.2023.116113_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2022.838259","article-title":"Biological membrane-penetrating peptides: computational prediction and applications","volume":"12","author":"de Oliveira","year":"2022","journal-title":"Front Cell. Infect. Microb."},{"key":"10.1016\/j.biopha.2023.116113_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114416","article-title":"The role of lipid components in lipid nanoparticles for vaccines and gene therapy","volume":"188","author":"Hald Albertsen","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2023.116113_bib73","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jconrel.2017.12.015","article-title":"Crossing the blood-brain barrier with nanoparticles","volume":"270","author":"Zhou","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2023.116113_bib74","doi-asserted-by":"crossref","first-page":"1216445","DOI":"10.1016\/j.biomaterials.2022.121645","article-title":"An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy","volume":"287","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"issue":"30","key":"10.1016\/j.biopha.2023.116113_bib75","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb4429","article-title":"Neurotransmitter-derived lipidoids (NT-lipidoids) for enhanced brain delivery through intravenous injection","volume":"6","author":"Ma","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2023.116113_bib76","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jconrel.2022.03.019","article-title":"Enhanced BBB and BBTB penetration and improved anti-glioma behavior of Bortezomib through dual-targeting nanostructured lipid carriers","volume":"345","author":"Farshbaf","year":"2022","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2023.116113_bib77","article-title":"Nanostructured lipid base carrier for specific delivery of garlic oil through blood brain barrier against aggressiveness of glioma","volume":"64","author":"Dana","year":"2021","journal-title":", J. Drug Deliv. Sci. Tech."},{"key":"10.1016\/j.biopha.2023.116113_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121395","article-title":"Comparison of three synthetic transferrin mimetic small peptides to promote the blood\u2013brain barrier penetration of vincristine liposomes for improved glioma targeted therapy","volume":"613","author":"Mojarad-Jabali","year":"2022","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib79","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.xphs.2021.11.022","article-title":"Synthesis and evaluation of high functionality and quality cell-penetrating peptide conjugated lipid for octaarginine modified PEGylated liposomes in U251 and U87 glioma cells","volume":"111","author":"El-Gamal","year":"2022","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.biopha.2023.116113_bib80","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1002\/jps.24186","article-title":"Enhanced glioma targeting and penetration by dual-targeting liposome co-modified with T7 and TAT","volume":"103","author":"Zong","year":"2014","journal-title":"J. Pharm. Sci."},{"issue":"17","key":"10.1016\/j.biopha.2023.116113_bib81","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.1016\/j.biomaterials.2014.02.031","article-title":"Paclitaxel loaded liposomes decorated with a multifunctional tandem peptide for glioma targeting","volume":"35","author":"Liu","year":"2014","journal-title":"Biomaterials"},{"issue":"32","key":"10.1016\/j.biopha.2023.116113_bib82","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1039\/C9NR03931G","article-title":"Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood\u2013brain barrier","volume":"11","author":"Shi","year":"2019","journal-title":"Nanoscale"},{"issue":"19","key":"10.1016\/j.biopha.2023.116113_bib83","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1039\/C9TB02700A","article-title":"Amphetamine decorated cationic lipid nanoparticles cross the blood\u2013brain barrier: therapeutic promise for combating glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Mater. Chem. B"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib84","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7150\/thno.41692","article-title":"Glioma stem cells and their roles within the hypoxic tumor microenvironment","volume":"11","author":"Boyd","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2023.116113_bib85","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jconrel.2017.11.026","article-title":"Dual-targeting immunoliposomes using angiopep-2 and CD133 antibody for glioblastoma stem cells","volume":"269","author":"Kim","year":"2018","journal-title":"J. Control Release"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib86","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3390\/molecules23010201","article-title":"Liposomal TriCurin, a synergistic combination of curcumin, epicatechin gallate and resveratrol, repolarizes tumor-associated microglia\/macrophages, and eliminates glioblastoma (GBM) and GBM stem cells","volume":"23","author":"Mukherjee","year":"2018","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib87","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1080\/10717544.2018.1494225","article-title":"Dual-modified cationic liposomes loaded with paclitaxel and survivin siRNA for targeted imaging and therapy of cancer stem cells in brain glioma","volume":"25","author":"Sun","year":"2018","journal-title":"Drug Deliv."},{"issue":"30","key":"10.1016\/j.biopha.2023.116113_bib88","doi-asserted-by":"crossref","first-page":"16792","DOI":"10.1021\/acsami.5b04596","article-title":"Multifunctional tandem peptide modified paclitaxel-loaded liposomes for the treatment of vasculogenic mimicry and cancer stem cells in malignant glioma","volume":"7","author":"Liu","year":"2015","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib89","first-page":"9","article-title":"Challenges in glioblastoma research: focus on the tumor microenvironment, Trends","volume":"9","author":"Bikfalvi","year":"2023","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib90","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1021\/acs.molpharmaceut.9b00065","article-title":"Targeted delivery of miRNA 155 to tumor associated macrophages for tumor immunotherapy","volume":"16","author":"Zang","year":"2019","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.116113_bib91","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.2147\/IJN.S207589","article-title":"Drug-free mannosylated liposomes inhibit tumor growth by promoting the polarization of tumor-associated macrophages","volume":"14","author":"Ye","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2023.116113_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.120057","article-title":"The impact of hypoxia on immune state in cancer","volume":"286","author":"Mortezaee","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2023.116113_bib93","first-page":"1","article-title":"Exosome-mediated crosstalk between tumor cells and innate immune cells: implications for cancer progression and therapeutic strategies","author":"Kwantwi","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"24","key":"10.1016\/j.biopha.2023.116113_bib94","article-title":"Theranostic nanomedicine for synergistic chemodynamic therapy and chemotherapy of orthotopic glioma","volume":"7","author":"Tan","year":"2020","journal-title":"Adv. Sci. (Weinh.)"},{"issue":"18","key":"10.1016\/j.biopha.2023.116113_bib95","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.7150\/thno.26225","article-title":"Hypoxia-responsive lipid-poly-(hypoxic radiosensitized polyprodrug) nanoparticles for glioma chemo- and radiotherapy","volume":"8","author":"Hua","year":"2018","journal-title":"Theranostics"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188616","article-title":"Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance","volume":"1876","author":"Tomar","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2023.116113_bib97","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejpb.2021.08.011","article-title":"Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers","volume":"168","author":"Delello Di Filippo","year":"2021","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"5-6","key":"10.1016\/j.biopha.2023.116113_bib98","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1159\/000360295","article-title":"Carmustine (BCNU) plus Teniposide (VM26) in recurrent malignant glioma","volume":"86","author":"Mack","year":"2014","journal-title":"Oncology"},{"issue":"12","key":"10.1016\/j.biopha.2023.116113_bib99","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.3390\/biom11121841","article-title":"Flavonoids synergistically enhance the anti-glioblastoma effects of chemotherapeutic drugs","volume":"11","author":"Zhai","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib100","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/pharmaceutics15020687","article-title":"Glioblastoma multiforme: probing solutions to systemic toxicity towards high-dose chemotherapy and inflammatory influence in resistance against temozolomide","volume":"15","author":"Nasir","year":"2023","journal-title":"Pharmaceutics"},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib101","doi-asserted-by":"crossref","first-page":"970","DOI":"10.17344\/acsi.2021.6977","article-title":"Lomustine incorporated lipid nanostructures demonstrated preferential anticancer properties in C6 glioma cell lines with enhanced pharmacokinetic profile in mice","volume":"68","author":"Satapathy","year":"2021","journal-title":"Acta Chim. Slov."},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib102","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.3109\/10717544.2015.1058434","article-title":"Vincristine and temozolomide combined chemotherapy for the treatment of glioma: a comparison of solid lipid nanoparticles and nanostructured lipid carriers for dual drugs delivery","volume":"23","author":"Wu","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2023.116113_bib103","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejpb.2018.09.012","article-title":"Design of multifunctional peptide collaborated and docetaxel loaded lipid nanoparticles for antiglioma therapy","volume":"132","author":"Kadari","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"26","key":"10.1016\/j.biopha.2023.116113_bib104","doi-asserted-by":"crossref","first-page":"29037","DOI":"10.1021\/acsami.0c05556","article-title":"Hybrid magnetic nanovectors promote selective glioblastoma cell death through a combined effect of lysosomal membrane permeabilization and chemotherapy","volume":"12","author":"Pucci","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib105","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10393","article-title":"\"Guide\" of muscone modification enhanced brain-targeting efficacy and anti-glioma effect of lactoferrin modified DTX liposomes","volume":"8","author":"Qi","year":"2023","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.biopha.2023.116113_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111461","article-title":"Paclitaxel and naringenin-loaded solid lipid nanoparticles surface modified with cyclic peptides with improved tumor targeting ability in glioblastoma multiforme","volume":"138","author":"Wang","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib107","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1080\/10717544.2021.1992038","article-title":"Ligand-modified homologous targeted cancer cell membrane biomimetic nanostructured lipid carriers for glioma therapy","volume":"28","author":"Chen","year":"2021","journal-title":"Drug Deliv."},{"key":"10.1016\/j.biopha.2023.116113_bib108","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jconrel.2019.06.033","article-title":"Dual functionalized liposomes for efficient co-delivery of anti-cancer chemotherapeutics for the treatment of glioblastoma","volume":"307","author":"Lakkadwala","year":"2019","journal-title":"J. Control Release"},{"issue":"11","key":"10.1016\/j.biopha.2023.116113_bib109","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1016\/j.xphs.2018.07.020","article-title":"Dual functionalized 5-fluorouracil liposomes as highly efficient nanomedicine for glioblastoma treatment as assessed in an in vitro brain tumor model","volume":"107","author":"Lakkadwala","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.116113_bib110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jconrel.2018.03.006","article-title":"Transferrin-targeted, resveratrol-loaded liposomes for the treatment of glioblastoma","volume":"277","author":"Jhaveri","year":"2018","journal-title":"J. Control Release"},{"key":"10.1016\/j.biopha.2023.116113_bib111","doi-asserted-by":"crossref","first-page":"7035","DOI":"10.2147\/IJN.S255902","article-title":"In vivo glioblastoma therapy using targeted liposomal cisplatin","volume":"15","author":"Ashrafzadeh","year":"2020","journal-title":"Int J. Nanomed."},{"issue":"32","key":"10.1016\/j.biopha.2023.116113_bib112","doi-asserted-by":"crossref","first-page":"15057","DOI":"10.1039\/C9NR03931G","article-title":"Glioma-targeted dual functionalized thermosensitive Ferri-liposomes for drug delivery through an in vitro blood-brain barrier","volume":"11","author":"Shi","year":"2019","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2023.116113_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114035","article-title":"Smart biomaterials to enhance the efficiency of immunotherapy in glioblastoma: State of the art and future perspectives","volume":"179","author":"Abadi","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib114","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"9","key":"10.1016\/j.biopha.2023.116113_bib115","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1002\/ijc.32531","article-title":"A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma","volume":"145","author":"Kim","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.biopha.2023.116113_bib116","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1484982","article-title":"Combination with SGT-53 overcomes tumor resistance to a checkpoint inhibitor","volume":"7","author":"Kim","year":"2018","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib117","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/cells10030484","article-title":"The many facets of therapy resistance and tumor recurrence in glioblastoma","volume":"10","author":"Goenka","year":"2021","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib118","article-title":"Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion","volume":"13","author":"Jiang","year":"2022","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib119","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/neuonc\/nov172","article-title":"PD-L1 expression and prognostic impact in glioblastoma","volume":"18","author":"Nduom","year":"2016","journal-title":"Neuro Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib120","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06430-1","article-title":"Dual-sgRNA CRISPR\/Cas9 knockout of PD-L1 in human U87 glioblastoma tumor cells inhibits proliferation, invasion, and tumor-associated macrophage polarization","volume":"12","author":"Fierro, Jr","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib121","article-title":"STING agonist-loaded, CD47\/PD-L1-targeting nanoparticles potentiate antitumor immunity and radiotherapy for glioblastoma","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib122","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1021\/acsnano.8b08177","article-title":"Radiation-induced targeted nanoparticle-based gene delivery for brain tumor therapy","volume":"13","author":"Erel-Akbaba","year":"2019","journal-title":"ACS Nano"},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib123","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1158\/1078-0432.CCR-15-1433","article-title":"Making better chimeric antigen receptors for adoptive T-cell therapy","volume":"22","author":"Maus","year":"2016","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.biopha.2023.116113_bib124","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.coph.2021.05.004","article-title":"Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond","volume":"59","author":"Moreno","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.biopha.2023.116113_bib125","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-vivo induced CAR-T cell for the potential breakthrough to overcome the barriers of current CAR-T cell therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front. Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2023.116113_bib126","doi-asserted-by":"crossref","first-page":"15688","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib127","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2020.05.005","article-title":"In vivo generation of CAR T cells selectively in human CD4(+) lymphocytes","volume":"28","author":"Agarwal","year":"2020","journal-title":"Mol. Ther."},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib128","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nnano.2017.57","article-title":"In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers","volume":"12","author":"Smith","year":"2017","journal-title":"Nat. Nanotechnol."},{"issue":"7","key":"10.1016\/j.biopha.2023.116113_bib129","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.3390\/biomedicines10071738","article-title":"Site-specific considerations on engineered T cells for malignant gliomas","volume":"10","author":"Elmadany","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib130","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01247-x","article-title":"Cancer vaccines as promising immuno-therapeutics: platforms and current progress","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib131","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001243","article-title":"New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models","volume":"9","author":"Lopes","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.116113_bib132","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-018-0911-0","article-title":"EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiforme cell tumorigenesis","volume":"17","author":"Wang","year":"2018","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib133","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","article-title":"The current landscape of nucleic acid therapeutics","volume":"16","author":"Kulkarni","year":"2021","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/j.biopha.2023.116113_bib134","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.jconrel.2020.03.040","article-title":"Nucleic acid-based drug delivery strategies","volume":"323","author":"Tan","year":"2020","journal-title":"J. Control Release"},{"issue":"34","key":"10.1016\/j.biopha.2023.116113_bib135","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2207841119","article-title":"Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8(+) T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3, Supplement","key":"10.1016\/j.biopha.2023.116113_bib136","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.ijrobp.2021.07.838","article-title":"Versatile mRNA-nanoparticle platform for treatment of glioblastoma","volume":"111","author":"Grippin","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol Phys."},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib137","first-page":"372","article-title":"Immune modulatory nanoparticle therapeutics for intracerebral glioma","volume":"19","author":"Yaghi","year":"2017","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.biopha.2023.116113_bib138","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.neuroscience.2022.03.030","article-title":"Recent advances in the therapeutic strategies of glioblastoma multiforme","volume":"491","author":"Aldoghachi","year":"2022","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2023.116113_bib139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2052-8426-2-21","article-title":"Gene therapy for malignant glioma","volume":"2","author":"Okura","year":"2014","journal-title":"Mol. Cell Ther."},{"key":"10.1016\/j.biopha.2023.116113_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2022.121645","article-title":"An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy","volume":"287","author":"Liu","year":"2022","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2023.116113_bib141","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.omto.2022.05.010","article-title":"\u03b22-Adrenergic receptor agonist enhances the bystander effect of HSV-TK\/GCV gene therapy in glioblastoma multiforme via upregulation of connexin 43 expression","volume":"26","author":"Hosseindoost","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"653","key":"10.1016\/j.biopha.2023.116113_bib142","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl4106","article-title":"Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models","volume":"14","author":"Birocchi","year":"2022","journal-title":"Sci. Transl. Med."},{"issue":"15","key":"10.1016\/j.biopha.2023.116113_bib143","doi-asserted-by":"crossref","first-page":"4523","DOI":"10.1158\/1078-0432.CCR-05-1830","article-title":"In vitro drug response and molecular markers associated with drug resistance in malignant gliomas","volume":"12","author":"Fruehauf","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib144","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1021\/nn5014484","article-title":"A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival","volume":"8","author":"Kim","year":"2014","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib145","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.nano.2014.09.005","article-title":"A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme","volume":"11","author":"Kim","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2023.116113_bib146","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/IJN.S286221","article-title":"Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound","volume":"16","author":"Yang","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.biopha.2023.116113_bib147","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.3389\/fphar.2018.01194","article-title":"Tumor-associated fibronectin targeted liposomal nanoplatform for cyclophilin A siRNA delivery and targeted malignant glioblastoma therapy","volume":"9","author":"Saw","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.biopha.2023.116113_bib148","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.omto.2022.10.013","article-title":"Dual EGFR- and TfR-targeted gene transfer for sodium iodide symporter gene therapy of glioblastoma","volume":"27","author":"Spellerberg","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"11","key":"10.1016\/j.biopha.2023.116113_bib149","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/s00109-019-01843-4","article-title":"Co-delivery of GOLPH3 siRNA and gefitinib by cationic lipid-PLGA nanoparticles improves EGFR-targeted therapy for glioma","volume":"97","author":"Ye","year":"2019","journal-title":"J. Mol. Med."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib150","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1021\/acs.nanolett.7b05430","article-title":"Lipid-based liquid crystalline nanoparticles facilitate cytosolic delivery of siRNA via structural transformation","volume":"18","author":"He","year":"2018","journal-title":"Nano Lett."},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib151","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030333","article-title":"Therapeutic targeting of Stat3 using lipopolyplex nanoparticle-formulated siRNA in a syngeneic orthotopic mouse glioma model","volume":"11","author":"Linder","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib152","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.3390\/pharmaceutics15041169","article-title":"Thermosensitive cationic magnetic liposomes for thermoresponsive delivery of CPT-11 and SLP2 shRNA in glioblastoma treatment","volume":"15","author":"Lu","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2023.116113_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122341","article-title":"Hyaluronan decorated layer-by-layer assembled lipid nanoparticles for miR-181a delivery in glioblastoma treatment","volume":"302","author":"Passos Gibson","year":"2023","journal-title":"Biomaterials"},{"issue":"49","key":"10.1016\/j.biopha.2023.116113_bib154","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202312603","article-title":"Synthetic high-density lipoprotein-based nanomedicine to silence SOCS1 in tumor microenvironment and trigger antitumor immunity against glioma","volume":"62","author":"Yang","year":"2023","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"19","key":"10.1016\/j.biopha.2023.116113_bib155","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1039\/C9TB02700A","article-title":"Amphetamine decorated cationic lipid nanoparticles cross the blood-brain barrier: therapeutic promise for combating glioblastoma","volume":"8","author":"Saha","year":"2020","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2023.116113_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119693","article-title":"Hybrid lipid self-assembling nanoparticles for brain delivery of microRNA","volume":"588","author":"Campani","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.biopha.2023.116113_bib157","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.2147\/IJN.S241055","article-title":"Brain targeted gold liposomes improve RNAi delivery for glioblastoma","volume":"15","author":"Grafals-Ruiz","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"2","key":"10.1016\/j.biopha.2023.116113_bib158","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1021\/nn506248s","article-title":"Localized RNAi therapeutics of chemoresistant grade IV glioma using hyaluronan-grafted lipid-based nanoparticles","volume":"9","author":"Cohen","year":"2015","journal-title":"ACS Nano"},{"issue":"Pt 1","key":"10.1016\/j.biopha.2023.116113_bib159","article-title":"Hybrid lipid-biopolymer nanocarrier as a strategy for GBM photodynamic therapy (PDT)","volume":"242","author":"Barbosa","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2023.116113_bib160","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.actbio.2021.04.005","article-title":"Ultrasound-responsive nutlin-loaded nanoparticles for combined chemotherapy and piezoelectric treatment of glioblastoma cells","volume":"139","author":"Pucci","year":"2022","journal-title":"Acta Biomater."},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib161","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3390\/pharmaceutics15030751","article-title":"Hybrid magnetic lipid-based nanoparticles for cancer therapy","volume":"15","author":"Luiz","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.biopha.2023.116113_bib162","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/nnm-2018-0436","article-title":"Nutlin-loaded magnetic solid lipid nanoparticles for targeted glioblastoma treatment","volume":"14","author":"Grillone","year":"2019","journal-title":"Nanomedicine"},{"key":"10.1016\/j.biopha.2023.116113_bib163","doi-asserted-by":"crossref","DOI":"10.1016\/j.msec.2021.112330","article-title":"Unravelling the potential of graphene in glioblastoma therapy","volume":"128","author":"Foo","year":"2021","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"10.1016\/j.biopha.2023.116113_bib164","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.623760","article-title":"Triggered drug release from liposomes: exploiting the outer and inner tumor environment","volume":"11","author":"Franco","year":"2021","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.116113_bib165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.2174\/1389450117666160401125034","article-title":"Smart triggered release in controlled drug delivery","volume":"19","author":"Balaure","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"3","key":"10.1016\/j.biopha.2023.116113_bib166","doi-asserted-by":"crossref","first-page":"202","DOI":"10.2174\/1389450117666160401124624","article-title":"Smart drug delivery systems in cancer therapy","volume":"19","author":"Unsoy","year":"2018","journal-title":"Curr. Drug Targets"},{"issue":"17","key":"10.1016\/j.biopha.2023.116113_bib167","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201800485","article-title":"Rational design of redox-responsive and P-gp-inhibitory lipid nanoparticles with high entrapment of paclitaxel for tumor therapy","volume":"7","author":"Chen","year":"2018","journal-title":"Adv. Health Mater."},{"issue":"8","key":"10.1016\/j.biopha.2023.116113_bib168","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/j.drudis.2021.05.010","article-title":"Stimulus-responsive liposomes for biomedical applications","volume":"26","author":"Antoniou","year":"2021","journal-title":"Drug Discov. Today"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301911X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222301911X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:39Z","timestamp":1792096959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222301911X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":168,"alternative-id":["S075333222301911X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116113","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipid-based nanoparticles to address the limitations of GBM therapy by overcoming the blood-brain barrier, targeting glioblastoma stem cells, and counteracting the immunosuppressive tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.116113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"116113"}}